Fabre-Kramer/GSK Submit Gepirone ER For Major Depressive Disorder
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms are seeking to secure FDA approval of the first-in-class 5HT1a agonist with new data.
You may also be interested in...
Is Fabre-Kramer’s Gepirone Antidepressant Rising From The Dead After 8 Years?
Nothing has been heard about the major depressive disorder treatment since FDA issued a third “not approvable” letter in 2007; advisory committee to discuss NDA in December.
Third Strike For Gepirone ER: Fabre-Kramer/GSK Antidepressant “Not Approvable” Again
Antidepressant received two FDA “not approvable” letters when it was licensed to Organon.
Third Strike For Gepirone ER: Fabre-Kramer/GSK Antidepressant “Not Approvable” Again
Antidepressant received two FDA “not approvable” letters when it was licensed to Organon.